Additionally, the low level of phosphorylated YB-1 in normal tissue obtained from PT1 ex vivo and previously published data in vitro [19], as well as in colorectal cancer tissues [52] suggest that the proposed targeting strategy in our study might spare the normal tissue and thus generate a therapeutic window of opportunity for cancer treatment. The gene discussed is YBX1; the disease is cancer.